Abstract
Background The efficacy of convalescent plasma (CP) for the treatment of COVID-19 remains unclear.
Methods A matched cohort analysis of hospitalized patients with severe COVID-19. The impact of CP treatment on all cause in-hospital mortality was evaluated using univariate and multivariate Cox proportional-hazards models, and the impact of CP treatment on the time to hospital discharge was assessed using a stratified log-rank analysis.
Results 64 patients who received CP a median of 7 days after symptom onset were compared to a matched control group of 177 patients. Overall in-hospital mortality was 14.9%. There was no significant difference in the risk of in-hospital mortality between the two groups (adjusted hazard ratio [aHR] 0.93, 95% confidence interval [CI] 0.39 – 2.20). There was also no significant difference in the overall rate of hospital discharge (rate ratio [RR] 1.28, 95% CI 0.91 – 1.81), but a subgroup analysis of patients 65-years-old or greater who received CP demonstrated a significantly increased hospital discharge rate among these patients (RR 1.86, 95% CI 1.03 – 3.36). There was a greater than expected frequency of transfusion reactions in the CP group (2.8% reaction rate observed per unit transfused).
Conclusions The use of CP in this study was a safe treatment for COVID-19. There was no overall significant reduction of in-hospital mortality or increased rate of hospital discharge associated with the use of CP in this study, although there was a signal for improved outcomes among the elderly. Further adequately powered randomized studies should target this subgroup when assessing the efficacy CP treatment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This matched cohort study was an electronic chart review approved by the Institutional Review Board of Rhode Island Hospital.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data underlying this article are available in the article.
Abbreviations
- AI
- antibody index
- COVID-19
- coronavirus disease 2019
- CI
- confidence interval
- CP
- convalescent plasma
- HFNC
- high-flow nasal cannula
- HR
- hazard ratio
- ICU
- intensive care unit
- IQR
- interquartile range
- NIPPV
- non-invasive positive pressure ventilation
- RR
- rate ratio
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- SD
- standard deviation
- TACO
- transfusion-associated circulatory overload
- TRALI
- transfusion-related acute lung injury
